MedPath

ATVAC (Lactobacilli Therapeutic Vaccine study)

Phase 1
Conditions
Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Bacterial vaginosis (Nugent score 4 or above)
Registration Number
EUCTR2013-002918-12-HU
Lead Sponsor
Amvac Kft
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

1.18 years or above
2.Mentally competent
3.Written informed consent
4.Being able to comply with the protocol

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Hypersensitivity to formaldehyde, or any other of the components of Gynevac
2.Fever
3.Acute infectious disease
4.Immunosuppression
5.Acute polyarthritis
6.Serious cardiac, liver or kidney diseases
7.Abnormalities of the blood circulation or of the hemopoetic system
8.Ongoing antibiotic treatment
9.Use of any investigational drug within 30 days of V0
10. No former antibiotic treatment for any reasons in 14 days before study entry

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To establish the efficacy and safety of a 5-shot treatment period with lactobacilli vaccination in patients with bacterial vaginosis and gathering information about dosage regimen;Secondary Objective: Secondary endpoint is the change of vaginal pH during the treatment period.<br>Other secondary endpoints are the patients subjective evaluation and changes in IgA levels (Microbe specific immunoglobulin answer)<br>;Primary end point(s): Nugent score changes in Vaginal smear;Timepoint(s) of evaluation of this end point: 63 days
Secondary Outcome Measures
NameTimeMethod
Secondary end point(s): vaginal pH change,<br>;Timepoint(s) of evaluation of this end point: 63 days
© Copyright 2025. All Rights Reserved by MedPath